It was a difficult start to the week for Heron Therapeutics (HRTX). Monday saw shares plunge after the small-cap biotech received another CRL (complete response letter) for its experimental post-operative pain medication, HTX-011.Following the verdict, Stifel analyst Derek Archila acknowledges that the current sentiment surrounding HRTX is negative, but he remains optimistic about the candidate.“While we think investors are losing confidence/patience with HRTX on getting HTX-011 over the goal line (2 CRLs and a PDUFA extension), the issues raised by the FDA in the CRL appear to be of a minor nature, and management’s commentary on the conference call make us confident they are addressable. No issues in terms of clinical efficacy, safety or CMC were brought up in the CRL.” said Archila.HTX-011 was rejected because of four non-clinical issues. Three were linked to “confirming excipient exposure in pre-clinical reproductive toxicology studies,” and one was related to changing the manufacturing release specs.Management stated...
Jul.01 -- Bob Martin, Thor Industries chief executive officer, says sales of RV's have been surging as Americans look for new ways to get around the country. He speaks on "Bloomberg Markets."...
If you are looking for the best ideas for your portfolio you may want to consider some of Amana Mutual Funds top stock picks. Amana Mutual Funds, an investment management firm, is bullish on Qualcomm Inc (NASDAQ:QCOM) stock. In its Q4 2019 investor letter – you can download a copy here – the firm discussed […]...
If you are looking for the best ideas for your portfolio you may want to consider some of Amana Mutual Funds top stock picks. Amana Mutual Funds, an investment management firm, is bullish on Intuit Inc (NASDAQ:INTU) stock. In its Q4 2019 investor letter – you can download a copy here – the firm discussed […]...
The frantic global search for a vaccine or therapy for the coronavirus has sent the valuations of previously small cap biotechs to unimagined heights over a short period of time. There can’t be many better examples for the phenomenon than Inovio Pharmaceuticals (INO). Investors have cheered the progress of its COVID-19 DNA vaccine candidate INO-4800 by sending shares on a mightily impressive run – the stock is up by 505% since the turn of the year (even after today's 25% sell off).The massive gains, the richly valued $3.2 billion market cap and a track record that – while promising – has yet to yield any significant results have prompted a rethink at investment firm H.C. Wainwright.“We believe the risk/reward ratio for Inovio has increased significantly as many open questions remain,” said firm analyst Ram Selvaraju, “Including the strength and duration of neutralizing antibodies and T cell responses that may be generated...
